Bee bloom compositions, methods of extraction and uses thereof

Abstract

The present invention relates to purified compositions of bee bloom, methods of preparing the purified compositions of bee bloom and the use of bee bloom in the reducing and treatment of inflammation.

Claims

1. A topical anti-inflammatory composition comprising an effective amount of a beeswax bloom extract, wherein said extract is obtained by extracting beeswax bloom powder with aqueous ethanol, wherein the extract comprises at least one crude protein, at least one long chain fatty acid, and at least one peptide, wherein the extract comprises at least 1.5 times more C16:0 fatty acids than in beeswax expressed as mg/g, and at least 10 times more crude protein than in beeswax expressed as mg/g, and wherein said composition is formulated as a topical cream, ointment, gel, spray, lotion, shampoo or mousse.

2. The composition of claim 1 wherein from about 20-30% by weight of total fatty acids in the extract are omega n-9 fatty acids.

3. The composition of claim 1 comprising a ratio of C16:0 to C18:1n9 fatty acids of from about 1.4 to 1.6:1.

4. The composition of claim 1 comprising a ratio of C18:1n9 to C18:3n3 fatty acids of from about 5 to 7:1.

5. The composition of claim 1 comprising a ratio of C16:0 fatty acids to total crude protein of about from about 2.2 to 2.9:1.

6. A method of treating an inflammatory disease in a subject in need thereof comprising topically administering an effective amount of the composition of claim 1 to said subject.

7. A method of producing a beeswax bloom extract comprising: (a) obtaining a beeswax bloom powder; (b) suspending the beeswax bloom powder in aqueous ethanol to obtain a beeswax bloom solution; and (c) removing particulate matter from the beeswax bloom solution to obtain said extract, wherein the extract comprises at least one crude protein, at least one long chain fatty acid, and at least one peptide, and wherein the extract comprises at least 1.5 times more C16:0 fatty acids than in beeswax expressed as mg/g, and at least 10 times more crude protein than in beeswax expressed as mg/g.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) Embodiments of the present invention will now be described, by way of example only, with reference to the attached Figures, wherein:

(2) FIG. 1 is a plot of the results from an in vitro study showing the effect of Bee Bloom on the ovalbumin induced contractile response of sensitized rat intestine;

(3) FIG. 2 is a plot of the results from an in vitro study showing the effect of Bee Bloom on the ovalbumin-induced contractile response of sensitized rat intestine when normalized to the response of an antigen alone;

(4) FIG. 3 is a plot of the results from an in vitro study showing the effect of Bee Bloom as the ratio of Bee Bloom contractile response to the ovalbumin-induced contractile response of sensitized rat intestine; and,

(5) FIG. 4 is a plot of the results from an in vitro study showing the effect of Bee Bloom as the ratio of Bee Bloom contractile response with antigen to Bee Bloom contractile response with carbachol in sensitized rat intestine.

DETAILED DESCRIPTION OF THE INVENTION

(6) A detailed description of one or more embodiments of the invention is provided below along with accompanying figures that illustrate the principles of the invention. As such this detailed description illustrates the invention by way of example and not by way of limitation. The description will clearly enable one skilled in the art to make and use the invention, and describes several embodiments, adaptations, variations and alternatives and uses of the invention, including what we presently believe is the best mode for carrying out the invention. It is to be clearly understood that routine variations and adaptations can be made to the invention as described, and such variations and adaptations squarely fall within the spirit and scope of the invention.

(7) In other words, the invention is described in connection with such embodiments, but the invention is not limited to any embodiment. The scope of the invention is limited only by the claims and the invention encompasses numerous alternatives, modifications and equivalents. Numerous specific details are set forth in the following description in order to provide a thorough understanding of the invention. These details are provided for the purpose of example and the invention may be practiced according to the claims without some or all of these specific details. For the purpose of clarity, technical material that is known in the technical fields related to the invention has not been described in detail so that the invention is not unnecessarily obscured.

(8) In the present disclosure and claims (if any), the word comprising and its derivatives including comprises and comprise include each of the stated integers or elements but does not exclude the inclusion of one or more further integers or elements.

(9) As used herein, the term about in connection with a measured quantity, refers to the normal variations in that measured quantity, as expected by a skilled artisan making the measurement and exercising a level of care commensurate with the objective of measurement.

(10) As used herein, the singular forms a, an, and the include plural referents unless the context clearly dictates otherwise. For example, reference to a substituent encompasses a single substituent as well as two or more substituents, and the like.

(11) As used herein, the terms for example, for instance, such as, or including are meant to introduce examples that further clarify more general subject matter. Unless otherwise specified, these examples are provided only as an aid for understanding the applications illustrated in the present disclosure, and are not meant to be limiting in any fashion.

(12) As used herein, animal means any member of the animal kingdom, including preferably humans.

(13) As used herein, food or food product or food material means any safe, ingestible product for animal use, including human use, and includes functional foods, dietary supplements, nutraceuticals, and designer foods.

(14) As used herein natural health products refer to vitamins and minerals, herbal remedies, homeopathic medicines, and probiotics

(15) As used herein, functional food means a product that is similar in appearance to conventional foods that is consumed as part of a usual diet, but which has demonstrated physiological benefits, aside from the pure nutritive advantage.

(16) As used herein, nutraceutical means a non-pharmaceutical product prepared in the form of pills, powders, potions and in other medicinal forms not generally associated with food but which has a physiological benefit or provides protection against disease or assists in the treatment of disease or a condition.

(17) As used herein, bioceutical refers a healthful compounds or compositions, extracted from natural plants and their derivatives.

(18) Anywhere in the world, nutraceuticals, functional foods, natural health products, bioceuticals, and designer foods may be supplemented with or comprise components which provide medical or health benefits, including the prevention and treatment of disease.

(19) As used herein, topical means the any topical surface of a subject (e.g., patient), such as skin (including under the scalp), nasal, sinus, vaginal, penile, urinary or anal surfaces.

(20) As used herein, treatment means the management and care of a patient for the purpose of combating an inflammatory disease, disorder or condition. The term is intended to include the alleviation, amelioration or relief of symptoms and complications, and/or the cure or elimination of the disease, disorder or condition.

(21) The terms therapeutically effective amount or effective amount refers to the amount of composition required in order to achieve the desired therapeutic or cosmetic effects.

(22) As used herein, the term bloom (also called fat bloom) refers to the film that forms on the surface of the lipid-based wax composition (surface fat bloom) or in homogeneities of beta (.beta.) phase crystals that resemble a loosely packed powder within the lipid-based wax composition (internal fat bloom). The principle of fat bloom is generally understood to be the transformation of a wax from a metastable phase to a more thermodynamically stable phase. Since fat bloom is a thermodynamically driven process, it will eventually occur in a lipid-based wax composition that is not in its most thermodynamically favoured state, such as a wax composition in the beta prime (.beta.) phase. Although the .beta. phase is not the most thermodynamically favoured state, the composition of a candle can be designed such that the transformation of the wax from the .beta. phase to .beta. phase is on the order of years instead of months or days. Fat bloom can also be exacerbated by storage of a candle at an elevated temperature, which can provide the necessary thermal energy for the lipid-based wax composition to undergo phase transformations. Fat crystals on the surface grow in size over time to first produce a dull appearance, with a white or light gray colored deposit on the surface, relative to what was once a glossy surface. Before the white deposit becomes visible, the product usually becomes dull and hazy having lost the high gloss surface. Although texture of the overall product may not be seriously altered by the early stages of fat bloom, the dull appearance and white deposit make it look old and stale to the consumer. Fat bloom may also exhibit itself as growths, which look like cauliflower, forming on the surface or interior of a candle, typically after burning it and then allowing the melt pool to re-solidify.

(23) With respect to beeswax, bloom rises to the surface of a candle when some of the low melting components of the wax migrate to the surface of the candle [13]. It is however, a generally unreported beeswax product. Searches, using the key words beeswax and bloom, in the databases, MEDLINE (OVID), PubMed, Web of Science, and Biological Sciences, did not provide any references to the use of bloom and its composition. The low melting components that compose bloom have not been identified. Beeswax extracted bloom has not experienced the scientific scrutiny observed for other bee products.

(24) Bloom also forms on the cuticular waxes produced by plants and is thought to provide protection against insect parasites, as it reduces attachment surfaces and gives a less adhesive surface [15,16]. Aside from this mechanical function, other actions or effects of beeswax bloom are not known, although the bloom on beecombs appears to have no effects on bees [17], and anti-predator actions have not been discussed.

(25) As noted above, bee bloom is a dusty coating that forms on beeswax over time that is understood to be low melting point components of the beeswax that migrate to the surface of beeswax. In particular, it is commonly seen on aged beeswax candles.

(26) In accordance with the invention, methods of extracting bee bloom, bee bloom compositions and the use of bee bloom are described. In particular, bee bloom is shown to exhibit anti-inflammatory properties as shown by in vitro studies done to study the effect of bee bloom on allergic reactions with intestinal tissues.

(27) Methods of Extraction and Purification

(28) In accordance with the invention, there is provided a method of extracting bee bloom from beeswax comprising the step of: solubilizing bee bloom within an aqueous solvent to produce a bee bloom solution. In another embodiment, step a. includes scraping bee bloom powder from the exterior surfaces of beeswax, suspending the scraped bee bloom powder within the aqueous solvent and removing particulate matter from the aqueous solvent.

(29) Aqueous solvent refers to a substance that acts as a dissolving agent or that is capable of dissolving another substance. The most common solvent is water. Other common solvents which dissolve substances that are insoluble (or nearly insoluble) in water are acetone, alcohol, formic acid, acetic acid, formamide. BTX, carbon disulfide, dimethyl sulfoxide, carbon tetrachloride, chloroform, ether, tetrahydrofuran, furfural, and hexane. They may be classified as polar and non-polar. Polar solvents, like water, have molecules whose electric charges are unequally distributed, leaving one end of each molecule more positive than the other. Usually polar solvent has OH bond of which water (HOH), (CH.sub.3OH) and acetic acid (CH.sub.3COOH) are examples. Propanol, butanol, formic acid, formamide are polar solvents. Dipolar solvents which contain a CO solid bond without OH bond are acetone [(CH.sub.3).sub.2CO], ethyl acetate (CH.sub.3COOCH.sub.2CH.sub.3), methyl ethyl ketone, acetonitrile, N,N-dimethylformamide and dimethyl sulfoxide. Non-polar solvents, like carbon tetrachloride (CC1.sub.4), benzene (C.sub.6H.sub.6), and diethyl ether (CH.sub.3CH.sub.2OCH.sub.2CH.sub.3), have molecules whose electric charges are equally distributed and are not miscible with water. Hexane, tetrahydrofuran and methylene chloride are non-polar solvents. Polar solvents are hydrophilic but non-polar solvents are lipophilic. Polar reactants will dissolve in polar solvents. Non-polar solvents dissolve non-polar compounds best. Oil and water don't mix but separate into two layers. There are three measures of the polarity as dipole moment, dielectric constant and miscibility with water. Though low dipole moments and small dielectric constants indicates non-polar solvents, sharp boundaries between polar and non-polar solvents are not available. The polarity reflects the balance between a polar component (OH) and a non-polar hydrocarbon component, existing in the same molecule. If hydrocarbon character increases relatively, the polarity decreases. On an operational basis, solvents that are miscible with water are polar.

(30) Preferably, the aqueous solvent comprises one or more hydrophilic components. Alternatively, the aqueous solvent is selected from the group comprising acetone, alcohol, formic acid, acetic acid, formamide. BTX, carbon disulfide, dimethyl sulfoxide, carbon tetrachloride, chloroform, ether, tetrahydrofuran, furfural, and hexane. More preferably, the solvent is aqueous alcohol although other alcohols including, but not limited to methanol and propanol may be used. Most preferably the solvent is aqueous ethanol.

(31) In a more preferred form, the extraction method comprises: a) Removing bloom from a wax material to form raw bloom; b) Drying the raw bloom to form a dry bloom; c) Dissolving the dry bloom in an aqueous solvent, as described above.

(32) In a preferred embodiment, the wax material is from beeswax. In a further preferred embodiment, the beeswax or wax material is one or more beeswax candles or was blocks. Drying may occur by evaporation, heating or any other conventional drying step. In a most preferred embodiment, dry bloom is dissolved at step c) in a hydrophilic mixture of alcohol and water (most preferably ethanol and water).

(33) In another embodiment, the concentration of bee bloom in the bee bloom solution is 1.0 mg/ml or greater.

(34) Compositions Extracted from Bloom

(35) In certain preferred embodiments, the compositions of the invention as extracted and purified from wax bloom comprise one or more proteins, fatty acids and peptides.

(36) More preferably, the composition comprises from about 20-30% by weight of the total fatty acids as omega fatty acids, most preferably as omega n-9 fatty acids. Omega n-9 fatty acids (popularly referred to as -9 fatty acids) are a family of unsaturated fatty acids which have in common a final carbon-carbon double bond in the n-9 position; that is, the ninth bond from the end of the fatty acid. In a most preferred form, the composition comprises from 20-30% by weight of oleic acid.

(37) Proteins are biochemical compounds consisting of one or more polypeptides typically folded into a globular or fibrous form, facilitating a biological function. A polypeptide is a single linear polymer chain of amino acids bonded together by peptide bonds between the carboxyl and amino groups of adjacent amino acid residues.

(38) The classic assays for protein concentration in food are the Kjeldahl method and the Dumas method and are well known in the art. These tests determine the total nitrogen in a sample. If the amount of nitrogen is multiplied by a factor depending on the kinds of protein expected in the sample, the total protein can be determined. This value is known as the crude protein content.

(39) What has surprisingly been found is that the compositions are extracted and purified from wax bloom within the method of the present invention have significantly more crude protein than residual beeswax, and have a significantly higher concentration of long chain fatty acids as compared to beeswax. Even more preferably, the compositions that are extracted and purified from wax bloom have significantly more omega n-9 fatty acids that beeswax, significantly more C16:0 (palmitic acid) than beeswax, significantly more C18:3n3 (alpha linolenic acid) than beeswax, significantly more C24:0 (tetracosanoic acid) than beeswax. Although not intending to be bound by any one theory of action with respect to the anti-inflammatory properties of the composition of the present invention, it is suspected that the noted constituents provide the superior anti-inflammatory action in combination and at the elevated levels as compared to beeswax extracts.

(40) In one preferred form, the composition is a bee bloom extract comprising a ratio of C16:0 to C18:1 n9 of from about 1.4 to 1.6:1. In one preferred form, the composition is a bee bloom extract comprising a ratio of C18:1n9 to C18:3n3 of from about 5 to 7:1. In one preferred form, the composition is a bee bloom extract comprising a ratio of C16:0 to total crude protein of about from about 2.2 to 2.9:1.

(41) In a most preferred embodiment, the extract composition comprises the entire middle column of enumerated constituents in Table 1.

(42) Uses of Compositions

(43) It is contemplated that the composition of the present invention may be beneficially applied to animals in topical formulations to treat or ameliorate an inflammatory condition. For external application, the composition may be formed into creams, ointments, gels, sprays, lotions, skin tonics, shampoos or mousses. Skin sprays are generally composed of aerosolized copolymers, such as polyvinylpyrrolidone, vinyl acetate and the like, and may also function as a setting lotion. Skin gel preparations are similar to sprays in composition, but are in gel and alcohol free form, and can coat the skin. Skin mousse is foam released under pressure from an aerosolized can. A skin care composition may be formulated as a hydrophobic or hydrophilic cream, ointment, gel, emollient, spray, lotion, skin tonic, shampoo or mousse, suitably with additional (optional) ingredients suitable for use in skin care compositions of types known in the art, and such further ingredients can include petrolatum, waxes, lanolin, silicone, liposomes, vegetable, mineral oils, plasticizers, fragrances, preservatives, a penetration enhancing agent, a pH adjusting agent or other suitable ingredients for topical skin compositions. Such ingredients can moisturize skin, stabilize the active compound, increase drug-skin contact and local concentration, control drug slow release, and/or aid in decreasing skin breakage, preventing skin atrophy, fibrosis and infection, and promoting skin wound healing, if desired.

(44) The present invention further provides a method of treating or ameliorating an indication of non-mucosal topical tissue comprising periodically applying to such disease or condition affected tissue a composition comprising an effective amount of an appropriate composition of the wax bloom extract.

(45) The invention further comprises applying the composition onto or within a portion of a film, patch or an adhesive solid formulation. The invention also provides lotions, gels, creams, ointments or suppositories comprising: an effective amount of appropriate composition of herbal bioactive comprising active(s) as described herein, optionally wherein the composition further forms a mucoadhesive coating on mucosal surfaces.

(46) The compositions of the invention can be formulated in any of the many compositions used in topical or mucosal treatments. For example, the compositions can be formulated as baths or soaks, solutions, lotions, gels, creams, ointments, suppositories, dressings adapted to release the compositions, instillation solutions, foams, or the like. In certain embodiments, the compositions are applied in reservoir or adhesive patches, or in films (such as described in US2007/149902).

(47) In certain embodiments, the combination is formulated in a lotion, gel, cream, ointment or suppository.

(48) Other Dosage Forms

(49) The present invention provides a method for treating or preventing inflammation including coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation and inflammation associated with wounds, acute pain and surgical procedures which comprises administering to an animal, a non-toxic and therapeutically effective amount of a composition comprising extracted and purified wax bloom.

(50) It has surprisingly been found that the extracts and compositions of the present invention exhibit superior anti-inflammatory activity and as such have a wide variety of therapeutic and cosmetic applications.

(51) In certain embodiments, the composition is administered in conjunction with another administration form, such as a film, patch or mucoadhesive solid dosage form. This solid dosage form can be applied before, concurrently, or after administration of the composition. The solid forms can help deliver medicament to more severely affected, or more mechanically accessible tissue, while the composition delivers medicament elsewhere. The medicament in the solid form can be the same or different from that of the compositions of the invention. For example, the dosage forms described in WO 02/094300 and U.S. Pat. No. 7,285,295 can be employed. Or, the film described in the an application, filed Jun. 20, 2007, titled Anti-Inflammatory Dissolvable Film, Ser. No. 11/765,587, can be employed.

(52) In certain embodiments, the other dosage form is adapted for systemic administration, such as by oral dosage form or by i.v.

(53) The desired effects described herein may be achieved in a number of different ways. The compounds and compositions of the present invention may be administered by any conventional means available for use in conjunction with pharmaceuticals, nutraceuticals, foods, beverages, and the like.

(54) A pharmaceutical composition for treating inflammation including coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation and inflammation associated with wound, acute pain and surgical procedures said composition comprises a wax bloom extract as described herein and an optional adjuvant or carrier.

(55) A method for treating and reducing inflammation including coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation and inflammation associated with wounds, acute pain and surgical procedures which comprises administering to an animal, a non-toxic and therapeutically effective amount a wax bloom extracts as described herein and an optional adjuvant or carrier.

(56) Dosages

(57) The amount of the compound or composition which is required to achieve the desired therapeutic or cosmetic effects will, of course, depend on a number of factors such as the mode of administration and the condition and size of the animal (subject to be treated). Such dose adaptation is well within the purview of someone skilled in the art.

(58) However, as a guideline, assuming a molecular weight of about 300 Daltons for the active ingredients in the bloom extract, an effective clinical dose of the composition, when administered orally may be as follows, based on per kg weight of subject: From about 100g/kg to 3 mg/kg More preferably from about 100g/kg to 1 mg/kg More preferably from about 500 g/kg to 800g/kg narrow range

(59) Lower doses than those ascribed above may be sufficient for topical applications, and could possibly be about 10 g to 1 mg per dose (or even lower); i.e. at least 70 times less than needed with oral ingestion.

(60) The compounds and compositions of the present invention can be administered to a patient either by: Topical application Within pharmaceutical compositions where they are mixed with suitable carriers or excipients for oral, buccal, or other conventional use. Mixed within foods Mixed within beverages Mixed within nutraceuticals Mixed within dietary supplements such as vitamins and chewables Combined as part of bioceutical formulation

(61) Use of physiologically acceptable carriers to formulate the compounds and compositions herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compounds and compositions of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds and compositions can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds and compositions of the invention to be formulated as tablets, pills, capsules (including soft gel capsules), liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

(62) Pharmaceutical compositions, comprising one or more of the compounds of the present invention, include compositions wherein the active ingredients are contained in an effective amount to achieve their intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

(63) In addition to the active ingredients these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.

(64) The delivery compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

(65) Formulations for parenteral administration include aqueous solutions of the bloom extraction composition in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

(66) Preparations for oral use can be obtained by combining the active compositions with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include lactose, sucrose, mannitol, sorbitol, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

(67) Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

(68) Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

(69) Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

(70) In another form of the present invention, the compounds and compositions of the present invention may be administered through foods, beverages and nutraceuticals, including, without limitation, the following: 1) Dairy Productssuch as cheeses, butter, milk and other dairy beverages, spreads and dairy mixes, ice cream and yoghurt; 2) Fat-Based Productssuch as margarines, spreads, mayonnaise, shortenings, cooking and frying oils and dressings; 3) Cereal-Based Productscomprising grains (for example, bread and pastas) whether these goods are cooked, baked or otherwise processed; 4) Confectioneriessuch as chocolate, candies, chewing gum, desserts, non-dairy toppings (for example Cool Whip), sorbets, icings and other fillings; 5) Beverageswhether alcoholic or non-alcoholic and including colas and other soft drinks, juice drinks, dietary supplement and meal replacement drinks such as those sold under the trade-marks Boost and Ensure; and 6) Miscellaneous Productsincluding eggs and egg products, processed foods such as soups, pre-prepared pasta sauces, pre-formed meals and the like.

(71) The compounds and compositions of the present invention may be incorporated directly and without further modification into the food, nutraceutical or beverage by techniques such as mixing, infusion, injection, blending, dispersing, emulsifying, immersion, spraying and kneading. Alternatively, the compounds and compositions may be applied directly onto a food or into a beverage by the consumer prior to ingestion. These are simple and economical modes of delivery.

(72) While the forms of composition, method and process described herein constitute preferred embodiments of this invention, it is to be understood that the invention is not limited to these precise forms. As will be apparent to those skilled in the art, the various embodiments described above can be combined to provide further embodiments. Aspects of the present composition, method and process (including specific components thereof) can be modified, if necessary, to best employ the systems, methods, nodes and components and concepts of the invention. These aspects are considered fully within the scope of the invention as claimed. For example, the various methods described above may omit some acts, include other acts, and/or execute acts in a different order than set out in the illustrated embodiments.

(73) Further, in the methods taught herein, the various acts may be performed in a different order than that illustrated and described. Additionally, the methods can omit some acts, and/or employ additional acts.

(74) These and other changes can be made to the present systems, methods and articles in light of the above description. In general, in the following claims, the terms used should not be construed to limit the invention to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the invention is not limited by the disclosure, but instead its scope is to be determined entirely by the following claims.

EXAMPLES

Example 1

Extraction and Purification Steps

(75) Materials and Methods

(76) Bee bloom was obtained by scraping beeswax candles with a scalpel. The wax candles were acquired through a local retailer and were all obtained from the same batch. The beeswax candles were roughly 1-2 weeks old prior to use. The wax in the beeswax candles were from a chemical free farm. No vitamin E, nut oil or animal by products were included in the wax.

(77) The candles were stored in sealed glass jars at an ambient temperature of 15 C. for several weeks, which was sufficient time for bloom to appear on the surface of the candle, The candles were scraped and the scrapings were collected into a glass container sealed with a metal lid and stored at 15 C. The product obtained from scraping the candles contained beeswax contaminants which were removed by extraction with alcohol. The Bee Bloom could also be isolated from beeswax by washing it with a water/ethanol mixture with or without mechanical effects such as agitation and/or sonication.

(78) Bee Bloom was extracted from the beeswax scrapings into a 1 ml mixture of 70% ethanol and 30% filtered water. The solution was sonicated 5 times for 1 minute and the resulting suspension centrifuged at 500 rpm (approx. 40 grams of force) for 3 minutes to remove large particulate matter. The particulate matter was primarily beeswax. The supernatant was collected and stored in 500 ml aliquots at 20 C. A reference stock solution contained 10 mg/ml Bee Bloom and the dilutions used in the study were in nanograms (ng/ml; 10.sup.9 g/ml). All dilutions from the stock solution (supernatant) were made in Krebs buffer. Sample sizes used for the study are shown in Table 1.

(79) TABLE-US-00001 TABLE 1 N-values for different doses of Bee Bloom added to millilitre of organ bath volume. Nanograms/ml N 100.0 7 35.0 5 10.0 7 3.5 5 1.0 7

Example 2

In Vivo Rat Study

(80) Statistical Analysis

(81) Data are expressed as the mean +/ standard error. The data were analyzed using Student's t test for paired samples. Significant differences were accepted if p <0.05. Outlier analysis was performed using a modified Z-score that uses the median of absolute deviation A Z-score with an absolute value of greater than 4.0 was labeled as a potential outlier, and the corresponding data value was excluded.

(82) Animals

(83) Male Sprague Dawley rats (Charles River Laboratories, Montreal, QC) of initial weights of 150 g were maintained with lights on from 700 to 1900 h and given food and water ad libitum. The rats were sensitized to 1 mg ovalbumin (OA) using 50 ng of pertussis toxin (Sigma-Aldrich, St. Louis, Mo.) as an adjuvant.

(84) In Vitro Anaphylaxis

(85) Five to eight weeks following sensitization, the terminal duodenum of the rats was excised and 1 cm sections were mounted in 25 ml organ baths, containing bicarbonate Krebs buffer, with 1.0 g of tension. The isometric force generated in response to OA and carbachol (CAR; (2-[(aminocaronyl)oxyl-N,N,N-trimethylethanaminium), a cholinergic agonist, (Sigma-Aldrich) was measured using a Grass Force Displacement Transducer FTO3 (Quincy, MA>. Data were recorded with PolyView software (Polybytes, Inc., Cedar Rapids, Iowa). The tissues were allowed to equilibrate for 30 min during which they were washed several times with buffer, and applied tension was adjusted.

(86) Eight tissue segments were mounted in separate tissue baths, with one tissue segment serving to evaluate if the intestinal tissues elicit a contractile response to the antigen. The other tissues were treated with one of the concentrations of Bee Bloom. A minimum of 4 intestinal segments from 4 different animals wore used for each dose of Bee Bloom. In the absence of a contractile response to antigen the tissues were discarded, and another animal taken.

(87) A control anti-allergic compound (the peptide D-phenylalanine-D-glutamate-Glycine (feG)) was used at a dose of 10.sup.8 M. This compound is a Control in the Figures.

(88) Anti-anaphylactic properties of the Bee Bloom were determined by adding Bee Bloom to separate baths and incubating for 10 min, before challenging with 1 mg of the AR antigen. Once peak contractile responses were attained the tissues were washed three times, baseline re-established and peak contractile response to 10.sup.5M CAR obtained. The mucosa was then scraped from the tissue, and the mass of the muscle determined. Responses were determined as grams of force/mg wet tissue.

(89) Contractile responses to OA and CAR were measured at peak contraction, and calculated as grams of force per gram wet tissue. Results are expressed in three formats: i) the amplitude of the OA-induced contractile response (grams of force/mg wet tissue), ii) the ratio of the Bee Bloom response to the OR response (Bee Bloom/OA) (i.e. animal matched control), iii) the ratio of the OA and CAR-induced contractile responses (ONCAR) (i.e. tissue matched controls).

Example 2A

Effect of Bee Bloom on Allergic Reactions with Intestinal Tissues

(90) OA-Induced Contractile Response

(91) Two doses of Bee Bloom (3.5 and 35 ng/ml) significantly inhibited antigen-elicited contractions of the sensitized rat intestine when data are presented in g tension/g tissue (FIG. 1). When normalized to the antigen (OR) response, three doses (3.5, 10 and 35 ng/ml) of Bee Bloom exhibited a significant inhibition of the antigen-induced contractions (FIG. 2). These differences reflect an abnormally higher response (outlier) at the 10 ng/ml dose of Bee Bloom. The control significantly inhibited the antigen-induced contractions.

(92) Ratio of the Bee Bloom Response to the OA Response

(93) When the ratio of the contractile responses of Bee Bloom and CA was considered (i.e. animal matched control), Bee Bloom gave significant inhibition of the antigen-induced contractions of the sensitized rat intestine at 3.5, 10 and 35 ng/ml (FIG. 3). The control significantly inhibited the antigen-induced contractions.

(94) Ratio of the OA and CAR-Induced Contractile Responses

(95) With the OA:CAR ratios (i.e. tissue matched controls) Bee Bloom gave significant inhibition of the antigen-induced contractions of the sensitized rat intestine at 35, 10 and 35 ng/ml (FIG. 4). The control did not significantly inhibit the OA:CAR ratio.

(96) Discussion

(97) Bee Bloom at doses of 3.5, 10 and 35 ng/ml significantly inhibited antigen-induced contractions of the sensitized rat intestine. This inhibition was observed for raw data (FIGS. 1 and 2), animal-matched controls (FIG. 3), and tissue-matched controls (FIG. 4). The 40% inhibition seen with Bee Bloom matches closely that seen with the control.

(98) The method used to extract Bee Bloom would favour the collection of lipid molecules, although some hydrophilic proteins would also be extracted. Although bee pollen is the precursor for all bee products (propolis, royal jelly, honey, beeswax, bee bread and Bee Bloom), bee pollen and Bee Bloom have distinct compositions since Bee Bloom was dissolved in a relatively hydrophilic mixture of water and ethanol, whereas solvents with low hydrophilicity, such as dichloromethane, or chloroform:methanol mixtures, are used to extract bees wax. Water:ethanol extraction would tend to isolate the free fatty acids, free primary fatty alcohols and proteins rather than the wax esters and straight hydrocarbons.

(99) Bee bloom in accordance with the invention may be effective in the treatment of inflammation in a variety of forms including incorporation into topical skin creams, lozenges, and capsules.

(100) Although the present invention has been described and illustrated with respect to preferred embodiments and preferred uses thereof, it is not to be so limited since modifications and changes can be made therein which are within the full, intended scope of the invention as understood by those skilled in the art.

Example 3

Bloom Extract Analysis

(101) POS was contracted to extract and analyze the composition of bloom from beeswax. In addition, the storage conditions for bloom development were evaluated.

(102) Objectives

(103) 1 Evaluation of storage conditions suitable for bloom development. 2. Extraction of bloom from beeswax using the method provided by the client. 3. Compositional analyses (including total phenolic content, residual solvents, fatty acid composition, total fatty alcohol content, crude protein content and elemental analysis) of bee bloom and residual beeswax.
1. Materials and Methods
1.1 Materials

(104) Beeswax (blocks and candles) were used for the processing trials.

(105) Anhydrous ethanol used for the bloom extraction was purchased from Commercial Alcohols, Winnipeg, MB.

(106) 1.2 Equipment

(107) Vacuum oven: Fisher ISOTEMP vacuum oven model 281 (Fisher Scientific, Toronto, ON).

(108) Rotary Vacuum Evaporator: Buchi Rotavapor R-151 rotary vacuum evaporator (Brinkmann Instruments, Mississauga, ON).

(109) Processing Methods

(110) Bloom Development

(111) To increase surface area for bloom development on the Beeswax blocks and candles, some blocks were liquefied and poured into shallow rectangular dishes to form beeswax sheets. Beeswax sheets and blocks were stored at room temperature both in the dark as well as under the light. As per client request, one sample of wax sheet was kept in a glass vacuum jar at room temperature. In addition, three candles were burned for 4 hours, and then stored in the dark to aid bloom development (24).

(112) Bloom Extraction

(113) Beeswax candles, blocks and sheets were scrapped with a metal spatula. Bloom was extracted according to the method provided in example 1. After extraction, both bloom and residual beeswax was dried in a rotatory evaporator and vacuum oven to obtain the total dry weight. Dried bloom was then dissolved in 100 ml 70% ethanol and held in a refrigerator prior to compositional analyses.

(114) Compositional Analyses

(115) The vacuum oven dried bloom extract and residual beeswax were subjected to the following analyses:

(116) Crude protein: AOCS Ba 4e-93

(117) Total fatty acid composition: AOAC 969.33

(118) Total phenolic content: modified method of Slinkard and Singleton method (29) Total fatty alcohol: modified method of Jimenez et al (25))

(119) In addition, residual beeswax was subjected to the following analyses:

(120) Elemental analysis: AOCS Ca20-99

(121) Residual solvent: AOCS Cg 4-94

(122) Results and Discussion

(123) Bloom Development

(124) Bloom Extraction

(125) A total of 0.59 g dried bloom was extracted and dissolved in 100 ml 70% ethanol. The bloom/ethanol stock solution (5.9 g/ml), which was light yellow in color, were stored in a refrigerator and used for compositional analyses. A white fluffy precipitate was observed when the solution was stored in refrigerator.

(126) Compositional Analysis

(127) Total phenolic content, crude protein, total fatty acids and total fatty alcohols content of both the bloom and residual beeswax are shown in Table 2. The crude protein content, which was estimated based on the total nitrogen present in the sample, was significantly higher in the bloom extract compared to that of the residual beeswax. According to the literature (25), hydroxy fatty acids were observed in beeswax, however, due to the difference of GC column, hydroxy fatty acid was not identified in the present analysis. No fatty alcohol was detected in the bloom extract whereas four saturated fatty alcohols were identified in the residual beeswax.

(128) Some studies have suggested that the anti-allergic effect of bee pollen, which contains about 35% protein, may be attributed to the presence of phenolic compounds, higher aliphatic primary alcohols and lipid-soluble components in pollen (26, 27 and 28). In the current study, phenolic content and aliphatic alcohols in residual beeswax were significantly higher than those in bloom extract. However, nitrogen-containing compounds (such as protein, peptides, amino acids), C16:0, C18:1n9 and C18:3n3 were significantly higher in the bloom composition of the present invention.

(129) TABLE-US-00002 TABLE 2 Compositional analysis of bloom extract and residual beeswax. Analyses (expressed as mg/g sample) Bloom extract Residual beeswax Total phenolic content.sup.1 3.2 248 Crude protein 40.8 3.4 Total fatty acid composition.sup.2 C12:0 1.3 0.3 C14:0 1.9 0.4 C15:0 0.2 ND C16:0 115.8 60.1 C16:1n7 2.0 0.2 C17:0 0.3 ND C17:1 0.4 0.1 C18:0 7.3 2.6 C18:1n9 71.8 10.7 C18:1 0.7 0.1 C18:2 7.7 0.2 C18:3n3 11.8 6.1 C18:4 ND 0.2 C20:0 1.3 1.0 C20:1 2.2 0.6 C20:5n3 ND 0.2 C22:0 8.4 2.7 C22:1n9 0.8 0.1 C21:5n3 ND 0.1 C22:4n6 0.3 14.7 C22:5n6 0.4 0.2 C24:0 21.3 27.4 C24:1n9 1.7 ND Others 10.1 4.6 Total fatty acids 267.7 132.6 Total Saturates 157.8 94.5 Total monounsaturates 79.6 11.8 Total polyunsaturates 20.2 21.7 Total omega 3 11.8 6.6 Total omega 6 8.4 13.1 Total omega 9 76.5 11.4 Total fatty alcohol.sup.3 C24:0 ND 0.69 C26:0 ND 0.62 C28:0 ND 0.74 C30:0 ND 1.7 .sup.1Total phenolic content is expressed as mg gallic acid equivalent per g sample. .sup.2Only common fatty acids are listed here. Unusual fatty acids, such as hydroxy fatty acids and branched chain fatty acids, were not analyzed. .sup.3Saturated fatty alcohols up to 30 carbon chain length were identified. ND: not detected.

(130) Residual solvent and elemental analysis of residual beeswax were shown in Table 3. Due to the limited amount of bloom extract sample, residual solvent and presence of elements were not measured.

(131) TABLE-US-00003 TABLE 3 Residual solvent (ethanol) and elemental analysis of residual beeswax. Analyses Residual beeswax Residual solvent Ethanol <1.0 ppm Elemental analysis Phosphorus 5.60 ppm Magnesium 0.94 ppm Potassium <0.50 ppm Sodium <0.50 ppm Calcium 9.26 ppm Copper <0.05 ppm Iron 1.38 ppm

REFERENCES

(132) 1. Fields D. The Health Benefits of Bee Products. 2010 [cited 2010 Oct. 25, 2010]; Available from: http://www.suite101.com/content/the-benefits-of-bee-products-a292871. 2. Lyngheim L, Scagnetti J. Bee Pollen: Nature's Miracle Health Food, Hollywood, Calif.: Wilshire Book Company, 1979. 3. Hellner M, Winter D, von Georgi R, Munstedt K. Apitherapy: usage and experience in german beekeepers. Evid Based complement Alternat Mod 2008; 5(4):475-479. 4. Campos M, Markham K R, Mitchell K A, Proenca da Cunha A. An Approach to the Characterization of Bee Pollens via their Flavonoid/Phenolic Profiles. PHYTOCHEMICAL ANALYSIS 1 997; 8:1 81-185. 5. Stickl H, Kerscher G. (Treatment of hay fever with new pollen capsules]. Fortschr Med I 980; 98(1 0):343-346. 6. Ishikawa Y, Tokura T, Ushlo H, Niyonsaba F, Yamamoto '1, Tadokoro T, et al. Lipid-soluble components of honeybee-collected pollen exert antiallergic effect by Inhibiting IgE-mediated mast cell activation in vivo. Phytother Res 2009; 23(10:1581-1586. 7. Mendoza S, Noa M, Perez Y, Mas R. Preventive effect of D-002, a mixture of long-chain alcohols from beeswax, on the liver damage induced with CCI4 in rats. J Med Food 2007; 1 O(2):379-383. 8. Mas R. D-002. Drugs of the Future 2001; 26:731-744. 9. Garcia M, del Pozo M D, Diez J, Munoz 0, de Corres L F. Allergic contact dermatitis from a beeswax nipple-protective. Contact Dermatitis 1 995; 33(6):440-441. 10. Harper J I, Gray W, Wilson-Jones E. Cryoglobulinaemia and angiomatosis. Br J Dermatol 1 983; 1 09(4):453-458. 11. Jensen C D, Andersen K E. Allergic contact dermatitis from cera alba (purified propolis) in a lip balm and candy. Contact Dermatitis 2006; 55(5):31 2-313. 12. Rajpara S, Wilkinson M S, Kng C M, Gawkrodger D J, English J S, Statham B N, et al. The importance of propolis in patch testinga multicentre survey. Contact Dermatitis 2009; 61 (5): 287-290. 13. Van Allen J. Annie's Apitherapy. 2010 [cited 2010; Available from: http://www.anniesapitherapy.com/beeswax.htm. 14. Small A V, Small AVSmaII AVs; Beecomb Foundation, assignee. Title Unknown. U.S. Pat. No. 2,494,907. 1947. 15. Duotting P S, Ding H, Neuteld J, Eigenbrode S D. Plant waxy bloom on peas affects infection of pea aphids by Pandora necaphidis. J lnvertebr Pathol2003; 84(3):149-158. 16. Eigenbrode S D. The effects of plant epicuticular waxy blooms on attachment and effectiveness of predatory insects. Arthropod Struct 0ev 2004; 33(1):91-102. 17. Lyttle S. Lyttle P. New Zealand Beeswax Ltd. 2010 Oct. 10, 2010 [cited 2010 Oct. 25, 2010]; Welcome to New Zealand Beeswax Ltd. http://www.beeswax.co.nZ/iflfOrmatiOrLhtm. 18. Metwally E, Pires J M, Moore G J, Bet us D A, Davison J S, Mathison ft Submandibular gland tripeptide FEG (Phe-Glu-Gly) and analogues: keys to structure determination. Peptides 200223(1):1 93-199. 19. Kosecka U, Marshall J S, Crowe S E, Bienenstock J, Perdue MI-I. Pertussis toxin stimulates hypersensitivity and enhances nerve-mediated antigen uptake in rat intestine. Am J Physic! 1994; 267(5 Pt 1):G745-753. 20. Iglewicz B, Hoaglin D. Volume 16: How to Detect and Handle Outliers, 1993. 21. Methods NSe-HoS. Detection of Outlierspage1.3.5.17. 2010 [cited 2010 Jul. 30, 2010]; Available from: httpl/www.itl.nist.gov/div898/handbook/ 22. lshikawa Y, Tokura T, Nakano N, Hara M, Niyonsaba F, Ushio H, et al, inhibitory effect of honeybee-collected pollen on mast cell degranulation in vivo and in vitro. J Med Food 2008; 11(1):14-20. 23. Medeiros K C P, Figueiredo C A V, Figueredo T B, Freire K R L, Santos F A R, Alcantara Neves N M, et al. Anti-allergic effect of bee pollen phenolic extract and myricetin in ovalbumin-sensitized mice. Journal of Ethnopharmacalogy 2008; 1 19:41-46. 24. How to Create Bloom on Beeswax Candles.http://www.ehow.com/how_4866142_create-bloom-beeswax-candles.htmlretrieved Nov. 8, 2011. 25. Jiminez, J. J., Bernal, J. L., Aumente, S., Toribio, J. B. Jr. (2003) Quality assurance of commercial beeswax 11. Gas chromatography-electron impact ionization mass spectrometry of alcohols and acids. Vol. 1007, 101-116. 26. Medeiros, K. C., Figueiredo, C. A., Figueredo, T. B., Freire, K. R., Santos, F. A, Alcantara-Neves, N. M., Silva, T. M., Piuvezam, M. R. (2008) Anti-allergic effect of bee pollen phenolic extract and myricetin in ovalbumin-sensitized mice. Vo 1.119, 41-46. 27. Mendoza, S., Noa, M., Pbez, Y., Mas, R. (2007) Preventive effect of D-002, a nixture of long-chain alcohols from beeswax, on the liver damage induced with CCI4 in rats. Vol. 10, 379-383. 28. Ishikawa, Y., Tohura, T., Niyonsaba, F., Yamamoto, Y., Tadokoso, T., Ogawa, H., Okumura, K. (2009) Lipid-soluble components of honeybee-collected pollen exert allergenic effect by inhibiting IgE-mediated mast cell activation in vivo. Vol. 23, 1581-1586. 29. Slinkard, K. & Singleton, V. L. (1977) Total Phenol Analysis: Automation and Comparison with Manual Methods. Am. J. Enol. Vitric, Vol. 28 (1). 49-55